The new codes are for describing the infusion of tixagevimab and cilgavimab monoclonal antibody (code XW023X7), and the infusion of other new technology monoclonal antibody (code XW023Y7).
The code K14.6 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions. The ICD-10-CM code K14.6 might also be used to specify conditions or terms like burning mouth syndrome, glossodynia or glossopyrosis.
The ICD-10-CM is a catalog of diagnosis codes used by medical professionals for medical coding and reporting in health care settings. The Centers for Medicare and Medicaid Services (CMS) maintain the catalog in the U.S. releasing yearly updates.
Oral mucositis (ulcerative), unspecified 1 K12.30 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. 2 The 2021 edition of ICD-10-CM K12.30 became effective on October 1, 2020. 3 This is the American ICD-10-CM version of K12.30 - other international versions of ICD-10 K12.30 may differ.
The 2022 edition of ICD-10-CM K12.30 became effective on October 1, 2021.